FDA delays AstraZeneca breast cancer drug camizestrant PDUFA date
read at Endpoints ↗RegulatoryNeutral
The U.S. Food and Drug Administration has extended the PDUFA target date for AstraZeneca’s breast cancer candidate camizestrant, pushing the review timeline back by a few days. No new deadline was disclosed in the announcement.
Arrowhead Pharmaceuticals disclosed that it is pursuing a therapy aimed at the same obesity related target that Wave is developing, highlighting growing competition in that therapeutic area.
The briefing also referenced updates from Kailera, Alfasigma, Junshi and Kura, though specific details were not provided.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “AstraZeneca's breast cancer PDUFA delayed; Arrowhead aims at same obesity target as Wave”
read at Endpoints ↗78 words · retrieved Jun 3
comments(0)
5-min edit window · permanent after that